Autonomix Medical Q2 FY26 net loss narrows 18.18% to $2.7 million
AMIX•Cash position and runway
Cash totaled $3.5 million, with working capital of $3.1 million; cash runway is expected into but not beyond Q1 2027.
Q2 FY26 financial results
Autonomix Medical posted a GAAP net loss of $2.7 million for the quarter ended June 30, 2026.
Total operating expenses fell 19% to $2.77 million, led by a 31% drop in general and administrative costs to $1.26 million.
Research and development spending edged down 5% to $1.52 million.
Recent financing and exchange compliance
In July, Nasdaq bid-price compliance was regained; a warrant inducement brought about $2.6 million in gross proceeds.
